Tumour budding in preoperative biopsy specimens is a useful prognostic index for identifying high-risk patients in early-stage (pN0) colon cancer

Background/aim: Tumour budding (BD) is considered a valuable prognostic factor in colon cancer (CC), but its use in daily practice isuncertain. We investigated the prognostic effect of BD using preoperative biopsy specimens in a fairly homogeneous population.Materials and methods: Eighty-two (pN0) CC patients who underwent surgery after preoperative biopsy between 1997 and 2013 wereincluded in the study. Model A (using the ‘deeply invasive blocks & hot-spot area & invasive margin) and method 1 (using the ‘20×objective & immunohistochemistry staining & quantitive counting’) were used as standard methods.Results: High BD was significantly associated with poor prognostic factors (lymphatic invasion [P = 0.008], perineural invasion [P =0.041], advanced pT [P = 0.015], invasive margin [P = 0.008], and margin involvement [P = 0.019]). Moreover, correlations betweendifferent BD estimates (r = 0.613–0.696), reproducibility of study (Κappa = 0.68–0.73), and usefulness of cut-off value (area of underROC = 0.746 [0.663–0.829]) were well. In univariate analysis, 5-year survival was poor in patients with high BD (relaps-free survival[RFS]: 71 %, P < 0.001; overall survival [OS]: 73 %, P = 0.004, local recurrence [LR]: 18 %, P = 0.032). Multivariate analyses confirmedthat high BD is an independent worse survival parameter for RFS (Hazard ratio [HR]: 1.53 [1.14–2.80], P = 0.015), OS (HR: 1.44[1.17–2.75], P = 0.032, and LR (HR: 1.59 [1.05–2.76], P = 0.045).Conclusion: Our data show that BD provides valuable prognostic information for early-stage (pN0) CC in preoperative biopsyspecimens and that adding BD to current risk classification may contribute to better patient selection.

PDF

___

1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76(2):182-188.
2. O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 2017; 18(7): 849-851.
3. Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(3): 370-398.
4. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal Clinical Oncology 2018; 23: 1-34.
5. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. European Journal of Cancer 2018; 96: 54-63.
6. De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. British Journal of Cancer 2017; 116: 58-65.
7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
8. Koelzer VH, Zlobec I, Lugli A. Tumour budding in colorectal cancer-ready for diagnostic practice? Human Pathology 2016; 47: 4-19.
9. De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Archiv 2016; 468: 397-408.
10. Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H et al. Prognostic value of Immunohistochemical analysis of tumour budding in colorectal carcinoma. Anticancer Research 2008; 28: 1831-1836.
11. Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. British Journal of Cancer 2016; 115: 831-840.
12. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G et al. Recommendations for reporting tumour budding in colorectal cancer based on the international tumour budding consensus conference (IBDCC) 2016. Modern Pathology 2017; 30: 1299- 1311
13. Gilardoni E, Bernasconi DP, Poli S, Garancini M, Luperto M et al. Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols. World Journal of Surgical Oncology 2015; 13: 260.
14. Zlobec I, Hadrich M, Dawson H, Koelzer VH, Borner M et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. British Journal of Cancer 2014; 110: 1008-1013.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, M Gion M, Clark GM. Reporting recommendations for tumour MARKer prognostic studies (REMARK). British Journal of Cancer 2005; 93:387-391.
16. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40: 127-132.
17. Zengin M. Prognostic role of Tumor-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population. Annals of Diagnostic Pathology 2019; 41: 69-78.
18. Zengin M. Local Inflammatory Response Can Predict Clinical Outcome in Patients with Curatively Resected Stage-IIB Colon Cancer: An Advanced Methodological Study. Pathology & Oncology Research 2019 Nov 20. doi: 10.1007/s12253-019- 00758-2
19. Kamarudin AN, Cox T, Kolamunnage-Dona R. Timedependent ROC curve analysis in medical research: current methods and applications. BMC Medical Research Methodology 2017; 17(1): 53.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159-74.
21. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficient. Psychological Methods 1996; 1: 30-46.
22. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989; 63(3): 539-543.
23. Giger O, Comtesse S, Lugli A, Zlobec I, Kurrer MO. Intratumoral budding (ITB) in pre-operative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Modern Pathology 2012; 2 (7): 1048-1053.
24. Rogers AC, Gibbons D, Hanly AM, Hyland JM, O’Connell PR et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Modern Pathology 2014; 27 (1): 156-162.
25. Koelzer VH, Assarzadegan N, Dawson H, Mitrovic B, Grin A et al. Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. The Journal of Pathology: Clinical Research 2017; 3: 171-178.
26. Karamitopoulou E, Zlobec I, Koelzer V, Terracciano L, Puppa G et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumour budding in colorectal cancer. Modern Pathology 2013; 26: 295-301.
27. Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson H et al. Tumour budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Archiv 2015; 466: 485-493
28. Lai YH, Wu LC, Li PS, Wu WH, Yang SB et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Color Disease 2014; 16: 259-264.
29. Betge J, Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A et al. Tumour budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Annals of Surgical Oncology 2012; 19: 3706-3712.
30. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumour budding as an index to identify high-risk patients with stage II colon cancer. Diseases of the Colon & Rectum 2008. 51: 568-572.
31. Yamada N, Sugai T, Eizuka M, Tsuchida K, Sugimoto R et al. Tumour budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition. Human Pathology 2017; 60: 151-159.
32. Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G et al. Tumour budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology 2013; 44: 697-705.
33. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumour stage. Cellular Oncology 2007; 29(5): 387-398
34. West NP, Dattani M, McShane P, Hutchins G, Grabsch J et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. British Journal of Cancer 2010; 102(10): 1519-1523.
35. van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treatment Reviews 2015; 41: 151-159.